We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

160 hedge funds and large institutions have $621M invested in Meridian Bioscience Inc in 2014 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 59 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 22

1% less funds holding

Funds holding: 161160 (-1)

11% less capital invested

Capital invested by funds: $695M → $621M (-$74.1M)

12% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 59

96% less call options, than puts

Call options by funds: $41K | Put options by funds: $1.06M

Holders
160
Holders Change
-1
Holders Change %
-0.62%
% of All Funds
4.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
52
Reduced
59
Closed
22
Calls
$41K
Puts
$1.06M
Net Calls
-$1.02M
Net Calls Change
+$782K
Name Holding Trade Value Shares
Change
Change in
Stake
State Board of Administration of Florida Retirement System
76
State Board of Administration of Florida Retirement System
Florida
$770K
Swiss National Bank
77
Swiss National Bank
Switzerland
$744K
HHC
78
Hutchin Hill Capital
New York
$709K +$739K +43,100 New
PC
79
Polar Capital
United Kingdom
$704K
Bank of America
80
Bank of America
North Carolina
$701K +$487K +28,405 +201%
DC
81
Deere & Company
Illinois
$684K
Tudor Investment Corp
82
Tudor Investment Corp
Connecticut
$672K +$282K +16,444 +67%
Ohio Public Employees Retirement System (OPERS)
83
Ohio Public Employees Retirement System (OPERS)
Ohio
$641K -$595K -34,655 -47%
SCA
84
Secor Capital Advisors
New York
$636K -$68.6K -4,001 -9%
CAI
85
Capital Advisors Inc
Oklahoma
$630K -$3.97M -231,265 -86%
TPSF
86
Texas Permanent School Fund
Texas
$617K -$3.5K -204 -0.5%
Nomura Holdings
87
Nomura Holdings
Japan
$589K +$613K +35,756 New
HCM
88
Hollencrest Capital Management
California
$583K +$92.6K +5,400 +18%
MLICM
89
Metropolitan Life Insurance Company (MetLife)
New York
$576K
HFS
90
HL Financial Services
Kentucky
$558K +$582K +33,912 New
JIM
91
Jensen Investment Management
Oregon
$540K +$563K +32,820 New
State of Tennessee, Department of Treasury
92
State of Tennessee, Department of Treasury
Tennessee
$535K -$56.6K -3,300 -9%
AIG
93
American International Group
New York
$521K -$33K -1,924 -6%
First Trust Advisors
94
First Trust Advisors
Illinois
$494K -$36.1K -2,107 -7%
TD Asset Management
95
TD Asset Management
Ontario, Canada
$492K +$46.3K +2,700 +10%
Verition Fund Management
96
Verition Fund Management
Connecticut
$482K +$277K +16,172 +123%
ASRS
97
Arizona State Retirement System
Arizona
$478K +$5.15K +300 +1%
VOYA Investment Management
98
VOYA Investment Management
Georgia
$471K -$117K -6,806 -19%
PAM
99
Princeton Alpha Management
New Jersey
$465K +$485K +28,259 New
MAM
100
Martingale Asset Management
Massachusetts
$439K +$5.32K +310 +1%

VIVO Hedge Fund Activity: Q4 2014 in Review

160 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q4 2014, worth a combined $621M — down 11% from $695M a quarter earlier.

Fund positioning in VIVO was balanced in Q4 2014: 22 funds opened new positions, 22 closed out, 52 added to existing stakes and 59 trimmed.

The largest buyer was Prudential plc, adding an estimated $5.95M. The largest seller was Bank of New York Mellon, cutting an estimated $25.5M.

  • 160 institutional investors held Meridian Bioscience Inc (VIVO) as of Q4 2014, down from 161 in Q3 2014.
  • Funds reported $621M of Meridian Bioscience Inc stock for Q4 2014, down 11% quarter-over-quarter.
  • 22 funds opened new Meridian Bioscience Inc positions in Q4 2014 and 22 closed out, a net change of 0 holders.
  • The largest Meridian Bioscience Inc buyer in Q4 2014 was Prudential plc, an estimated $5.95M added.
  • The largest Meridian Bioscience Inc seller in Q4 2014 was Bank of New York Mellon, an estimated $25.5M sold.

Based on aggregated 13F filings for Q4 2014.